How Do Cancer Drugs Help Rheumatoid Arthritis?

>human rheumatoid arthritis patients and found that it
Rheumatoid arthritis (RA) is a chronic inflammatoryreduced the processes associated with inflammation
autoimmune disease that affects 2 million Americans. Itand abnormal growth in the joints.
is not a benign disease. Up to half of those with theGleevec is the brand name of imatinib, a drug
disease are disabled after 15 years due to cripplingproduced by the pharmaceutical company Novartis
deformity. Many of the drugs currently used to treatAG. It is part of a class of drugs called kinase inhibitors,
rheumatoid arthritis (RA) were originally used to treatwhich act by blocking communication signals between
different kinds of cancers.cells. These signals, when they go awry, are often at
The first example is methotrexate. This drug is anthe root of diseases such as cancer and autoimmune
immunosuppressant that inhibits dihydrofolateconditions.
reductase. By doing this it inhibits the growth andGleevec targets kinase gene mutations seen in chronic
proliferation of lymphocytes which are important cellsmyelogenous leukemia or CML (a bone marrow
involved in the autoimmune process.cancer) as well as certain types of stomach cancers.
Another example is azathioprine (Imuran). This drugThe same kinases turn out to play a critical role in
inhibits T-lymphocytes, a population of lymphiocytesrheumatoid arthritis.
that are important in the initiation of autoimmunity.William Robinson, senior researcher, said that the field
Cyclophosphamide (Cytoxan) alkylates and crosslinksof autoimmune disease research has been trying to
DNA essentially poisoning cells. Neither azathioprine nordevelop kinase inhibitors for more than a decade. "We
cyclophosphamide are used much anymore forwere very surprised that Gleevec worked as well as it
rheumatoid arthritis because of toxicity issues. All threedid," said Robinson. "It just seemed too simple." The
drugs… methotrexate, azathioprine, andresults are especially encouraging since the drug is
cyclophosphamide are still used to treat variousalready FDA-approved, and has relatively few side
cancers.effects."
More recently, biologic treatments have been used toWe have taken a very potent kinase inhibitor and
treat RA. One biologic treatment that has performeddiscovered that it works very well for an autoimmune
well in RA is rituximab (Rituxan). This drug isdisease," said Robinson. "The significance is twofold.
considered one of the drugs of choice for theFirst, it might provide insights into the mechanisms
treatment of non-Hodgkins lymphoma. Rituximabunderlying rheumatoid arthritis by figuring out what
depletes a population of B cells called CD20. CD20Gleevec inhibits. “Second,” he added, “it might
cells are instrumental in the perpetuation of RA.represent a new therapeutic approach to rheumatoid
A recent intriguing study suggests another anti-cancerarthritis and other autoimmune diseases. The kinases
agent, Gleevec, may have promise in RA. Gleevec isthe drug inhibits likely play a role in other autoimmune
currently used to treat leukemia and somediseases, such as scleroderma, psoriasis and
gastrointestinal cancers.inflammatory bowel disease.”
Researchers at the Stanford University School ofRobinson said he hopes that in the near future, clinical
Medicine, led a team that set out to find drugs thattrials will be conducted that look at the drug's
might provide additional benefit to rheumatoid arthritiseffectiveness for a range of autoimmune diseases.
patients. They screened a range of drugs in mice that(Paniagua RT, Ho PP, Chan SM, Changf A, Higgins JP,
have a condition similar to human rheumatoid arthritis.Tomooka BH, Thomas FM, Song JJ, Goodman SB,
In their study, Gleevec almost completely preventedLee DM, Genovese MC, Utz, PJ, Steinman L, Robinson
the development of a rheumatoid arthritis-like diseaseWH. Selective tyrosine inhibition by imatinib mesylate
in mice. The drug also halted the progression offor the treatment of autoimmune arthritis. J Clin Invest.
established disease, significantly reducing the amount2006; 116: 2633-2642).
of inflammation and bone destruction around the joints.Note: Part of this story was adapted from a news
The researchers also tested Gleevec on the cells ofrelease issued by Stanford University Medical Center.